CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients
BackgroundTacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated wit...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01218/full |
| _version_ | 1819123518532485120 |
|---|---|
| author | Effrosyni Mendrinou Mohamed Elsayed Mashaly Amir Mohamed Al Okily Mohamed Elsayed Mohamed Ayman Fathi Refaie Essam Mahmoud Elsawy Hazem Hamed Saleh Hussein Sheashaa George P. Patrinos George P. Patrinos George P. Patrinos |
| author_facet | Effrosyni Mendrinou Mohamed Elsayed Mashaly Amir Mohamed Al Okily Mohamed Elsayed Mohamed Ayman Fathi Refaie Essam Mahmoud Elsawy Hazem Hamed Saleh Hussein Sheashaa George P. Patrinos George P. Patrinos George P. Patrinos |
| author_sort | Effrosyni Mendrinou |
| collection | DOAJ |
| description | BackgroundTacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated with tacrolimus dose requirement in renal transplant recipients.Materials and MethodsIn this study, we determined the allelic frequency of CYP3A5*3 in 76 renal transplanted patients of Egyptian descent. Secondly, we evaluated the influence of the CYP3A5 gene variant on tacrolimus doses required for these patients as well on dose-adjusted tacrolimus trough-concentrations.ResultsThe CYP3A5*3 variant was the most frequent allele detected at 85.53%. Additionally, our results showed that, mean tacrolimus daily requirements for heterozygous patients (CYP3A5*1/*3) were significantly higher compared to homozygous patients (CYP3A5*3/*3) during the first year after kidney transplantation.ConclusionThis is the first study in Egypt contributing to the individualization of tacrolimus dosing in Egyptian patients, informed by the CYP3A5 genotype. |
| first_indexed | 2024-12-22T07:09:37Z |
| format | Article |
| id | doaj.art-5e8c082dea184679acfbbc0bf8a3e0d1 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-22T07:09:37Z |
| publishDate | 2020-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-5e8c082dea184679acfbbc0bf8a3e0d12022-12-21T18:34:33ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-08-011110.3389/fphar.2020.01218566624CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted PatientsEffrosyni Mendrinou0Mohamed Elsayed Mashaly1Amir Mohamed Al Okily2Mohamed Elsayed Mohamed3Ayman Fathi Refaie4Essam Mahmoud Elsawy5Hazem Hamed Saleh6Hussein Sheashaa7George P. Patrinos8George P. Patrinos9George P. Patrinos10Department of Pharmacy, School of Health Sciences, University of Patras, Patras, GreeceThe Urology-Nephrology Center, Department of Dialysis and Transplantation, Mansoura University, Mansoura, EgyptDepartment of Nephrology, Zagazig University, Zagazig, EgyptDepartment of Nephrology, Zagazig University, Zagazig, EgyptThe Urology-Nephrology Center, Department of Dialysis and Transplantation, Mansoura University, Mansoura, EgyptUrology and Nephrology Center, Department of Laboratories, Mansoura University, Mansoura, EgyptUrology and Nephrology Center, Department of Laboratories, Mansoura University, Mansoura, EgyptThe Urology-Nephrology Center, Department of Dialysis and Transplantation, Mansoura University, Mansoura, EgyptDepartment of Pharmacy, School of Health Sciences, University of Patras, Patras, GreeceZayed Center of Health Sciences, United Arab Emirates University, Al-Ain, United Arab EmiratesDepartment of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab EmiratesBackgroundTacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated with tacrolimus dose requirement in renal transplant recipients.Materials and MethodsIn this study, we determined the allelic frequency of CYP3A5*3 in 76 renal transplanted patients of Egyptian descent. Secondly, we evaluated the influence of the CYP3A5 gene variant on tacrolimus doses required for these patients as well on dose-adjusted tacrolimus trough-concentrations.ResultsThe CYP3A5*3 variant was the most frequent allele detected at 85.53%. Additionally, our results showed that, mean tacrolimus daily requirements for heterozygous patients (CYP3A5*1/*3) were significantly higher compared to homozygous patients (CYP3A5*3/*3) during the first year after kidney transplantation.ConclusionThis is the first study in Egypt contributing to the individualization of tacrolimus dosing in Egyptian patients, informed by the CYP3A5 genotype.https://www.frontiersin.org/article/10.3389/fphar.2020.01218/fullCYP3A5kidney transplantationliving donortacrolimusEgyptian populationdose requirements |
| spellingShingle | Effrosyni Mendrinou Mohamed Elsayed Mashaly Amir Mohamed Al Okily Mohamed Elsayed Mohamed Ayman Fathi Refaie Essam Mahmoud Elsawy Hazem Hamed Saleh Hussein Sheashaa George P. Patrinos George P. Patrinos George P. Patrinos CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients Frontiers in Pharmacology CYP3A5 kidney transplantation living donor tacrolimus Egyptian population dose requirements |
| title | CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients |
| title_full | CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients |
| title_fullStr | CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients |
| title_full_unstemmed | CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients |
| title_short | CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients |
| title_sort | cyp3a5 gene guided tacrolimus treatment of living donor egyptian kidney transplanted patients |
| topic | CYP3A5 kidney transplantation living donor tacrolimus Egyptian population dose requirements |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.01218/full |
| work_keys_str_mv | AT effrosynimendrinou cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT mohamedelsayedmashaly cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT amirmohamedalokily cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT mohamedelsayedmohamed cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT aymanfathirefaie cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT essammahmoudelsawy cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT hazemhamedsaleh cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT husseinsheashaa cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT georgeppatrinos cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT georgeppatrinos cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients AT georgeppatrinos cyp3a5geneguidedtacrolimustreatmentoflivingdonoregyptiankidneytransplantedpatients |